Janssen-developed clinical trials tech available for industry use

By Melissa Fassbender contact

- Last updated on GMT

Janssen Research & Development collaborated with Tata Consultancy Services (TCS) to build out the clinical trials platform. (Image: iStock/utah778)
Janssen Research & Development collaborated with Tata Consultancy Services (TCS) to build out the clinical trials platform. (Image: iStock/utah778)

Related tags: Clinical trial, Clinical trials, Clinicaltrials.gov

The new Software as a Service (SaaS) solution provides tools for clinical trials medication management and patient engagement.

The new platform features four modules including, communication, adherence, label, and tracking

The approach was developed by Janssen Research & Development as part of its integrated Smart Trial and Engagement Platform (iSTEP) initiative and will be made available for industry-use via Tata Consultancy Services (TCS) under the name Connected Clinical Trials (CCT).

Drug accountability and medication management are the most complex elements of a clinical trial. CCT automates this entire process and thereby removes guesswork from the clinical trial​,” a TCS spokesperson told Outsourcing-Pharma.com.

Moreover, CCT leverages a powerful device data acquisition and analytical framework that helps a clinical trial benefit from a variety of devices on a single platform. Each trial is unique in itself and CCT helps study teams flexibly manage variation across trials through extensive configuration capability​.”

The platform has been tested and proven in a live set-up at TCS' User Experience labs with global patient and site advisory boards in collaboration with the Center for Information and Study on Clinical Research Participation (CISCRP).

Additionally, Janssen has conducted a technical pilot and is working with health authorities and ethics committees to implement a pilot assessment of the technology in a clinical trial by the end of 2017.

Janssen plans to gradually implement iSTEP into clinical trials in its portfolio, according to the company.

Related news

Show more

Related products

show more

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us

Products

View more

Webinars